Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial

Abstract Background Proton-pump inhibitors (PPI) are liberally prescribed in patients with liver cirrhosis. Observational studies link PPI therapy in cirrhotic patients with an increased risk for infectious complications, hepatic encephalopathy and an increased risk for hospitalization and mortality...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Malte H. Wehmeyer, Thomas Horvatits, Anika Buchholz, Linda Krause, Sarah Walter, Antonia Zapf, Ansgar W. Lohse, Johannes Kluwe, the STOPPIT-trial group
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2022-04-01
Serie:	Trials
Soggetti:	PPI Pantoprazole Esomeprazole Side-effects Complications Liver cirrhosis
Accesso online:	https://doi.org/10.1186/s13063-022-06232-w
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!